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The adjuvant therapy in gastric adenocarcinoma is supported by the U.S. Intergroup INT-0116. To apply the
same treatment and see if the results are comparable
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Materials/methods. Retrospective study in 119 p. with gastric adenocarcinoma underwent to surgery R0-1 and D2 lymphadenec-
tomy who received adjuvant QTRT like INT-0116 scheme. Statistical material SPSS 20.0. Average age 62. Males 67.2%. By location,
antrum 47.9%, body 36.1%, cardia 2.5% multicenter 4.2%, pylorus 6.7%, stump 2.5%. Total gastrectomy 43.7%. Edge+microscopic
13.4%. Media of lymph nodes removed: 19.23 (0–55). Affected lymph nodes. Average: 6.5 (0–33).
Results. Complete adjuvant therapy 87.9%. Toxicity with hospital admission 31.3%. Stadium: pT1 3.4%, pT2 33.1%, pT3 50.8%, pT4
12.7%, pN0 17.6%, pN1 40.3%, ≥pN2 42%. Toxicity ≥G2: hematologic 46.2%, gastrointestinal 19.3%, pain 1.7%, infection 10.1%,
none 20.2%. Median follow up 54 months. Overall survival at 3 years was 53.2%. SLE 42 months. Relapse: local 3.4%, peritoneal
11.8%, distant 24.4%. Signiﬁcant prognostic factors in multivariate analysis: stage, vasculolymphatic inﬁltration and lymph node
affectation.
Conclusions. The results obtained in our study, even with adverse prognostic factors, are comparable to those presented by the
U.S. Intergroup and conﬁrm the efﬁcacy of treatment with acceptable toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.750
Toxicity in rectal cancer patients treated with neoadjuvant radiotherapy combined with capecitabine vs.
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Background and aim. Neoadjuvant treatment with concurrent radiochemotherapy improves local control in locally advanced
rectal cancer, however its toxicity proﬁle before and after surgery are still controversial. The aim of this retrospective study was
to evaluate the safety and tolerance of neoadjuvant chemoradiotherapy in rectal cancer patients treated either with capecitabine
or raltitrexed in combination with radiotherapy.
Methods. Retrospective data from 108 patients with locally advanced rectal cancer (T3-4 N0 M0/Tx N1–2 M0) treated preoperatively
with radiotherapy combined with oral capecitabine (825mg/m2 twice daily during radiotherapy) in 49 patients or intravenous
raltitrexed (3mg/m2 days 1-18-36) in 59 patients. The side effects of the treatment were evaluated in each group using The
Common Terminology Criteria for Adverse Events v.4.0.
Results. Toxicity grade 1–2 in patients treated with raltitrexed vs. capecitabine was as follows: vomiting 0 vs. 4.1%; diarrhea 30.5
vs. 42.9%; urinary 1.7 vs. 4.1%; radiodermatitis 37.3 vs. 26.6%; anemia 0% both; neutropenia 1.7 vs. 0%. Toxicity grade 3–4 in
patients treated with raltitrexed vs. capecitabine was as follows: vomiting 0% both; diarrhea 5.1 vs. 2,04%; urinary 3.4 vs. 0%;
radiodermatitis 6.8 vs. 2.04%; anemia 1.7 vs. 2,04%; neutropenia 1.7 vs. 0%.
Conclusions. Neoadjuvant radiotherapy associated with capecitabine or raltitrexed is well tolerated in rectal cancer patients, but
we can ﬁnd more events grade 3–4 in patients treated with raltitrexed. These data need to be conﬁrmed with prospective studies.
http://dx.doi.org/10.1016/j.rpor.2013.03.751
Triple drug docetaxel-based neoadjuvant treatment in gastric cancer: Long-term results
P.Martin Romano1, J. Rodriguez1, J. Diaz-gonzalez2, A. Chopitea1, C. Garzon1, J. Aristu2, E. Castan˜on1, J. Fusco1,
L. Zubiri 1, M. Rodriguez-ruiz2, A. Olarte2, L. Arbea Moreno2
1 Clinica Universitaria de Navarra, Oncologia Medica, Spain
2 Clinica Universitaria de Navarra, Oncologia Radioterapica, Spain
Purpose. To analyze the feasibility, toxicity and efﬁcacy of triple drug docetaxel-based induction chemotherapy (ICHT) and
chemoradiotherapy (CHT-RT) in patients with locally advanced gastric or gastroesophageal cancer.
Methods. Patients with diagnostic of T3–T4 and/or N0-N+ gastric or gastroesophageal adenocarcinoma were planned to receive
three cycles of ICHT with capecitabine, oxaliplatin and docetaxel, followed by 45Gy of tridimensional conformal radiotherapy
and concurrent capecitabine, oxaliplatin and docetaxel. Surgery was scheduled 4–6 weeks after completion of CHT-RT. Toxicity
